Serelaxin and acute heart failure

Heart

Volumn 102, Issue 2, 2016, Pages 95-99

  Tietjens, Jeremy ^a   Teerlink, John R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RELAXIN; SERELAXIN; CARDIOVASCULAR AGENT; RECOMBINANT PROTEIN; SERELAXIN PROTEIN, HUMAN;

ACUTE HEART FAILURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CELL PROTECTION; CLINICAL STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HEART HEMODYNAMICS; HEART PROTECTION; HUMAN; LENGTH OF STAY; MULTIPLE ORGAN FAILURE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; ACUTE DISEASE; DRUG EFFECTS; HEART FAILURE; HEMODYNAMICS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACUTE DISEASE; CARDIOVASCULAR AGENTS; HEART FAILURE; HEMODYNAMICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RELAXIN;

EID: 84959020583     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306786     Document Type: Review

References (35)

1. Voigt J, Sasha John M, Taylor A, et al. A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. Clin Cardiol 2014;37:312-21.
2. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015;131: e29-322.
3. Chen J, Normand SL, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 2011;306:1669-78.
4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-239.
5. Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013;61:391-403.
6. Mentz RJ, Felker GM, Ahmad T, et al. Learning from recent trials and shaping the future of acute heart failure trials. Am Heart J 2013;166:629-35.
7. Koniari K, Parissis J, Paraskevaidis I, et al. Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches. Eur Heart J Acute Cardiovasc Care 2012;1:256-68.
8. Felker GM, Pang PS, Adams KF, et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010;3:314-25.
9. Chapman AB, Abraham WT, Zamudio S, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 1998;54:2056-63.
10. Conrad KP. Maternal vasodilation in pregnancy: the emerging role of relaxin. Am J Physiol Regul Integr Comp Physiol 2011;301:R267-275.
11. Jelinic M, Leo CH, Post Uiterweer ED, et al. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 2014;28:275-87.
12. Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 2011;13:409-20.
13. McGuane JT, Debrah JE, Sautina L, et al. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 2011;152:2786-96.
14. Leo CH, Jelinic M, Parkington HC, et al. Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J Am Heart Assoc 2014;3:e000493.
15. Dschietzig T, Bartsch C, Richter C, et al. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 2003;92:32-40.
16. McGuane JT, Danielson LA, Debrah JE, et al. Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension. 2011;57:1151-60.
17. Dschietzig T, Teichman S, Unemori E, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009;15:182-90.
18. Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014;35:431-41.
19. Voors AA, Dahlke M, Meyer S, et al. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study. Circ Heart Fail 2014;7:994-1002.
20. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-39.
21. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
22. Felker GM, Teerlink JR, Butler J, et al. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. J Am Coll Cardiol 2014;64:1591-8.
23. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206.
24. Voors AA, Davison BA, Teerlink JR, et al. Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome-an analysis from RELAX-AHF. Eur J Heart Fail 2014;16:1230-40.
25. Wang TS, Hellkamp AS, Patel CB, et al. Representativeness of RELAX-AHF clinical trial population in acute heart failure. Circ Cardiovasc Qual Outcomes 2014;7:259-68.
26. Metra M, Ponikowski P, Cotter G, et al. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 2013;34:3128-36.
27. Filippatos G, Teerlink JR, Farmakis D, et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 2014;35:1041-50.
28. Mentz RJ, Kjeldsen K, Rossi GP, et al. Decongestion in acute heart failure. Eur J Heart Fail 2014;16:471-82.
29. Abrahamsson P, Swedberg K, Borer JS, et al. Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 2013;15:885-91.
30. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003;41:997-1003.
31. Sasser JM, Cunningham MW Jr, Baylis C. Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II induced hypertension. Am J Physiol Renal Physiol 2014:307:F1355-62.
32. Zhang J, Qi YF, Geng B, et al. Effect of relaxin on myocardial ischemia injury induced by isoproterenol. Peptides 2005;26:1632-9.
33. Samuel CS, Bodaragama H, Chew JY, et al. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension 2014;64:315-22.
34. Du XJ, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010;7:48-58.
35. Nistri S, Pini A, Sassoli C, et al. Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration. J Cell Mol Med 2012;16:507-19.